{"id":"bevacizumab-triamcinolone-acetonide","safety":{"commonSideEffects":[{"rate":"null","effect":"Hypertension"},{"rate":"null","effect":"Proteinuria"},{"rate":"null","effect":"Headache"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL1504","moleculeType":"Small molecule","molecularWeight":"434.50"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Bevacizumab works by binding to VEGF-A, preventing it from interacting with its receptor and thereby inhibiting angiogenesis. Triamcinolone acetonide, on the other hand, has anti-inflammatory properties that help to reduce swelling and alleviate symptoms.","oneSentence":"Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), while triamcinolone acetonide is a corticosteroid that reduces inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:05.914Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Nonsquamous non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT07014280","phase":"PHASE4","title":"Bevacizumab Versus Triamcinolone Acetonide for the Treatment of Keloids.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kasr El Aini Hospital","startDate":"2023-09-01","conditions":"Keloids","enrollment":28},{"nctId":"NCT06882551","phase":"PHASE4","title":"Comparison of Intravitreal Bevacizumab Injection with Combination of Suprachoroidal Triamcinolone Acetonide Along with Intravitreal Bevacizumab Injection in the Treatment of Diabetic Macular Edema in Pseudophakic Patients","status":"COMPLETED","sponsor":"Khyber Teaching Hospital","startDate":"2023-04-01","conditions":"Diabetic Macular Edema (DME)","enrollment":82},{"nctId":"NCT06559488","phase":"NA","title":"IVB for Post-vitrectomy Hemorrhage in Diabetic Eyes","status":"COMPLETED","sponsor":"Universitas Padjadjaran","startDate":"2018-04-02","conditions":"Diabetic Retinopathy, Vitreous Hemorrhage","enrollment":18},{"nctId":"NCT00555594","phase":"PHASE2, PHASE3","title":"Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization","status":"COMPLETED","sponsor":"Asociación para Evitar la Ceguera en México","startDate":"2006-09","conditions":"Corneal Neovascularization","enrollment":18},{"nctId":"NCT00600301","phase":"PHASE3","title":"Vitrectomy Without Internal Limiting Membrane Removal in the Treatment of Diffuse Diabetic Macular Edema: a Comparative Kenalog Vs Bevacizumab Intravitreal Injection Vs Control Study","status":"WITHDRAWN","sponsor":"Asociación para Evitar la Ceguera en México","startDate":"2008-01","conditions":"Diffuse Diabetic Macular Edema","enrollment":""},{"nctId":"NCT00566761","phase":"PHASE4","title":"Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO","status":"TERMINATED","sponsor":"Asociación para Evitar la Ceguera en México","startDate":"2007-06","conditions":"Macular Edema, Central Retinal Vein Occlusion","enrollment":10},{"nctId":"NCT04812977","phase":"NA","title":"Comparison of Intravitreal Anti-VEGF Versus Combination Therapy in Central Retinal Vein Occlusion","status":"COMPLETED","sponsor":"Hayatabad Medical Complex","startDate":"2018-06-10","conditions":"Central Retinal Vein Occlusion With Macular Edema","enrollment":30},{"nctId":"NCT02985619","phase":"PHASE2, PHASE3","title":"Bevacizumabe or Triamcinolone for Persistent Diabetic Macular Edema","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2016-07-21","conditions":"Diabetic Macular Edema","enrollment":100},{"nctId":"NCT03203447","phase":"PHASE3","title":"Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO","status":"TERMINATED","sponsor":"Clearside Biomedical, Inc.","startDate":"2018-03-05","conditions":"Macular Edema, Retinal Vein Occlusion","enrollment":325},{"nctId":"NCT01572350","phase":"PHASE3","title":"Safety and Efficacy of Triamcinolone Acetonide Combined With Laser, Bevacizumab Combined With Laser Versus Laser Alone for the Treatment of Diffuse Non-tractional Diabetic Macular Edema","status":"COMPLETED","sponsor":"Hospital Universitario de Canarias","startDate":"2010-10","conditions":"Diabetic Macular Edema","enrollment":105},{"nctId":"NCT00563940","phase":"","title":"Short-term Effects of Intravitreal Bevacizumab and Triamcinolone in Patients With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2007-03","conditions":"Diabetic Macular Edema","enrollment":30},{"nctId":"NCT01774474","phase":"PHASE3","title":"PRevention of Macular EDema After Cataract Surgery","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2013-07-10","conditions":"Cystoid Macular Edema, Cataract, Diabetes Mellitus","enrollment":1127},{"nctId":"NCT00737971","phase":"PHASE4","title":"Efficacy Study of Triamcinolone and Bevacizumab Intravitreal for Treatment of Diabetic Macular Edema","status":"COMPLETED","sponsor":"Rubens Belfort Jr.","startDate":"2008-08","conditions":"Diabetic Macular Edema","enrollment":142},{"nctId":"NCT00682539","phase":"PHASE4","title":"Intraocular Anti-VEGF Compared With Intraocular Triamcinolone in Patients With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2007-10","conditions":"Diabetic Macular Edema","enrollment":71},{"nctId":"NCT02310295","phase":"NA","title":"Prospective, Randomized Clinical Trial Comparing Macular Photocoagulation With or Without Intravitreal Bevacizumab or Triamcinolone for the Treatment of Diabetic Macular Edema","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2009-01","conditions":"Diabetic Macular Edema","enrollment":45},{"nctId":"NCT00997191","phase":"PHASE3","title":"Intravitreal Bevacizumab and Triamcinolone Associated to Laser Photocoagulation for Diabetic Macular Edema(IBeTA)","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2009-10","conditions":"Diabetic Macular Edema","enrollment":12},{"nctId":"NCT01614509","phase":"NA","title":"Combined Therapy of Posterior Subtenon Triamcinolone Acetonide and Intravitreal Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion","status":"COMPLETED","sponsor":"Yeungnam University College of Medicine","startDate":"2012-01","conditions":"Branch Retinal Vein Occlusion","enrollment":45},{"nctId":"NCT00805064","phase":"PHASE3","title":"Combined Triple Procedure in Retinal Vein Occlusion (RVO)","status":"COMPLETED","sponsor":"Johann Wolfgang Goethe University Hospital","startDate":"2006-01","conditions":"Retinal Vein Occlusion","enrollment":40},{"nctId":"NCT00806169","phase":"PHASE3","title":"Combined Triple Therapy in Diabetic Retinopathy (DRP)","status":"COMPLETED","sponsor":"Johann Wolfgang Goethe University Hospital","startDate":"2006-04","conditions":"Macular Edema, Diabetic Retinopathy","enrollment":40},{"nctId":"NCT01095809","phase":"PHASE3","title":"Efficacy, Safety and Tolerability of Repeated Dosis of Intravitreous Bevacizumab in Uveitic Macular Oedema","status":"TERMINATED","sponsor":"Hospital Clinic of Barcelona","startDate":"2010-04","conditions":"Uveitis","enrollment":5},{"nctId":"NCT00376701","phase":"PHASE2","title":"Combination Therapy for Age-Related Macular Degeneration.","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2006-09","conditions":"Age Related Macular Degeneration","enrollment":103},{"nctId":"NCT01342159","phase":"NA","title":"Intravitreal Bevacizumab and Triamcinolone in Diabetic Macular Edema","status":"COMPLETED","sponsor":"Hallym University Medical Center","startDate":"2009-03","conditions":"Diabetic Macular Edema","enrollment":80},{"nctId":"NCT01330524","phase":"PHASE1, PHASE2","title":"Comparison of Intravitreal Bevacizumab and Triamcinolone With Placebo","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2010-01","conditions":"Acute Nonarteritic Anterior Ischemic Optic Neuropathy","enrollment":16},{"nctId":"NCT00464347","phase":"PHASE2","title":"TAC-PF, Avastin® in Combination With Photodynamic Therapy to Treat Age Related Macular Degeneration","status":"TERMINATED","sponsor":"National Eye Institute (NEI)","startDate":"2007-01","conditions":"Age-Related Macular Degeneration","enrollment":100},{"nctId":"NCT00447031","phase":"NA","title":"Combination Therapy for Neovascular Age Related Macular Degeneration","status":"WITHDRAWN","sponsor":"Yonsei University","startDate":"2007-03","conditions":"Macular Degeneration","enrollment":""},{"nctId":"NCT01053858","phase":"NA","title":"Triamcinolone or Bevacizumab for Central Retinal Vein Occlusion With Poor Vision","status":"COMPLETED","sponsor":"Hallym University Medical Center","startDate":"2008-01","conditions":"Central Retinal Vein Occlusion With 20/200 or Worse Visual Acuity","enrollment":38},{"nctId":"NCT01044329","phase":"PHASE2","title":"Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Branch Retinal Vein Occlusion","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2010-01","conditions":"Branch Retinal Vein Occlusion","enrollment":90},{"nctId":"NCT00874744","phase":"PHASE2","title":"Comparison of Single Intravitreal Injection of Triamcinolone or Bevacizumab for the Treatment of Diabetic Macular Edema","status":"COMPLETED","sponsor":"Universidade Federal de Goias","startDate":"2008-03","conditions":"Diabetic Macular Edema","enrollment":13},{"nctId":"NCT00371111","phase":"PHASE1","title":"To Compare Therapeutic Effect of Intravitreal Bevacizumab and Triamcinolone in Resistant Uveitic Cystoid Macular Edema","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2006-08","conditions":"Resistant Cystoid Macular Edema","enrollment":40},{"nctId":"NCT00370370","phase":"PHASE3","title":"Intravitreal Bevacizumab vs. Bevacizumab Combined With Triamcinolone for Neovascular AMD","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2005-11","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":""},{"nctId":"NCT00468351","phase":"PHASE1","title":"Intravitreal Triamcinolone Acetonide Versus Intravitreal Bevacizumab for Refractory Diabetic Macular Edema (IBEME Study)","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"2006-04","conditions":"Diabetic Macular Edema","enrollment":""},{"nctId":"NCT00370422","phase":"PHASE3","title":"Bevacizumab Versus Combined Bevacizumab and Triamcinolone for Refractory Diabetic Macular Edema; a Randomized Clinical Trial","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2005-11","conditions":"Diabetic Macular Edema","enrollment":""},{"nctId":"NCT00370669","phase":"PHASE3","title":"Effect of Intravitreal Bevacizumab on Clinically Significant Macular Edema","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2005-11","conditions":"Diabetic Macular Edema","enrollment":150},{"nctId":"NCT00370630","phase":"PHASE2","title":"Intravitreal Avastin Versus Intravitreal Avastin and Triamcinolone in Central Retinal Vein Occlusion(CRVO)","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2006-08","conditions":"Retinovascular Disease","enrollment":15},{"nctId":"NCT00370539","phase":"PHASE3","title":"Combined PDT and Intravitreal Bevacizumab vs Combination of PDT, Intravitreal Bevacizumab and Triamcinolone for Neovascular AMD","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2006-09","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":262,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"bevacizumab + triamcinolone acetonide","genericName":"bevacizumab + triamcinolone acetonide","companyName":"Shahid Beheshti University of Medical Sciences","companyId":"shahid-beheshti-university-of-medical-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), while triamcinolone acetonide is a corticosteroid that reduces inflammation. Used for Metastatic colorectal cancer, Nonsquamous non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}